Modeling and Simulation Archives

Blog

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

2025 年 4 月 18 日 What’s next for drug development? Recapping our MIDD in the age of…

Danielle Pillsbury2025 年 4 月 18 日

Press Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…

Simona Colucci2025 年 4 月 14 日

Publication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…

Danielle Pillsbury2025 年 3 月 20 日

Publication

MIDD in Japan – Implementations, challenges and opportunities

In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…

Danielle Pillsbury2025 年 3 月 12 日

On-Demand Webinar

人工智能时代的模型引导的药物开发

Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…

Danielle Pillsbury2025 年 3 月 10 日

Publication

Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach

This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…

Danielle Pillsbury2025 年 3 月 4 日

Blog

药物开发中 PK/PD 建模的机器学习

Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…

Danielle Pillsbury2025 年 3 月 4 日

Fact Sheet

Pharmacometrics Drug Development Decision Support: 基于模型的荟萃分析（MBMA）

Danielle Pillsbury2025 年 2 月 19 日

Video

Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学（PK/PD）分析与建模平台

Today's drug candidates are more complex than ever. But with development decisions on the line,…

Danielle Pillsbury2025 年 2 月 12 日

Poster

利用模拟结果为探索全人源抗 IL-6 抗体 TOUR006 治疗甲状腺眼病的 IIb 期试验确定剂量

Danielle Pillsbury2025 年 2 月 7 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

建模与模拟

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

MIDD in Japan – Implementations, challenges and opportunities

人工智能时代的模型引导的药物开发

Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach

药物开发中 PK/PD 建模的机器学习

Pharmacometrics Drug Development Decision Support: 基于模型的荟萃分析（MBMA）

Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学（PK/PD）分析与建模平台

利用模拟结果为探索全人源抗 IL-6 抗体 TOUR006 治疗甲状腺眼病的 IIb 期试验确定剂量

订阅时事通讯

快捷链接

解决方案

联系我们